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IMPORTANCE Abiraterone acetate is combined with prednisone, 5 mg, twice daily for
metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once
daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer.
Understanding the physiological effects of these and other regimens is important.
OBJECTIVE To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens.
DESIGN, SETTING, AND PARTICIPANTS Open-label, randomized clinical trial (1:1:1:1) of 164men
with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4
intervention groups between June 2013 and October 2014. Analyses were conducted from
August 2017 to June 2018.
INTERVENTIONS Abiraterone acetate, 1000mg, once daily with prednisone, 5 mg, twice daily
(n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg,
once daily (n = 42).
MAIN OUTCOMES ANDMEASURES Primary end point was nomineralocorticoid excess (grade
1 hypokalemia or grade2 hypertension) through 24 weeks (6 cycles) from treatment.
RESULTS Of 164men (median [range] age, 70 [50-90] years) randomized to receive abiraterone
acetate, 1000mg,dailywithprednisone, 5mg, twicedaily, oncedaily, or 2.5mg twicedaily, or
dexamethasone,0.5mg, oncedaily, 24 (70.6%)of 34patients (95%CI, 53.8%-83.2%), 14
(36.8%)of 38patients (95%CI, 23.4%-52.7%), 21 (60.0%)of 35patients (95%CI, 43.6%-
74.4%), and26 (70.3%)of 37patients (95%CI, 54.2%-82.5%), respectively, hadno
mineralocorticoid excess. Plasmaadrenocorticotrophic hormoneandurinarymineralocorticoid
metabolites after8weekswerehigherwithprednisone, 2.5mg, twicedaily and5mgoncedaily
thanwith5mg twicedaily or dexamethasone,0.5mg, oncedaily. The level of urinary
glucocorticoidmetabolites appearedhigher inpatientswhodidnotmeet theprimary endpoint,
regardless of glucocorticoid regimen. Total leanbodymassdecreased in theprednisonegroups
and total body fat increased in theprednisone, 5mg, twicedaily anddexamethasonegroups.
In thedexamethasonegroup, therewas an increase in serum insulin andhomeostaticmodel
assessmentof insulin resistance,while total bonemineral density decreased. In theprednisone,
5mg, twicedaily, 5mgoncedaily, 2.5mg twicedaily, anddexamethasonegroups,median
radiographic progression-free survivalwas 18.5, 15.3, 12.8, and26.6months, respectively.
CONCLUSIONS AND RELEVANCE Abiraterone acetate with prednisone, 5mg, twice daily or
dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point
(95% CI excluded 50%mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg,
once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in
combination with dexamethasone appeared to be particularly active but may be associated
with adverse metabolic consequences.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01867710
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A birateroneacetate, 1000mg,oncedaily is approved foruse in combinationwitheitherprednisone, 5mg, twicedaily or prednisone, 5 mg, once daily based on phase
3 trials reporting improvements in overall survival for the for-
mer in patients with metastatic castration-resistant prostate
cancer (mCRPC)1,2 and for the latter innewly-diagnosed,high-
risk patients with metastatic castration-sensitive prostate
cancer.3 Prednisone, 5 mg, once daily was also used in phase
3 trials investigating the benefit of abiraterone acetate in hor-
mone-naïve advanced prostate cancer (STAMPEDE
[NCT00268476]4 and PEACE-1 [NCT01957436]). When ad-
ministered without glucocorticoids, abiraterone acetate in-
duces a syndromeof secondarymineralocorticoid excess due
to CYP17A1 17α-hydroxylase inhibition, consequently de-
creased glucocorticoid production, and a compensatory in-
crease in adrenocorticotrophic hormone (ACTH), resulting in
a rise in steroids withmineralocorticoid properties upstream
of CYP17A1.5,6 In addition tomaximizing efficacy for treating
prostate cancer, glucocorticoids are combined with abi-
raterone acetate to prevent this syndrome; however, gluco-
corticoidexposuremayexceedphysiological requirements.Dif-
ferent glucocorticoid combination regimens have not been
formally tested with abiraterone acetate. Because prolonged
exposure to abiraterone acetate plus glucocorticoid is ex-
pected fromearlier use, there is anurgentneed to improveun-
derstandingof thephysiological effects of these treatments to
improve individualized treatment.
We aimed to evaluate administration of abiraterone ac-
etate with prednisone, 5 mg, twice daily, the lower dose of 5
mg once daily used in metastatic castration-sensitive pros-
tate cancer trials,3,4,7 and prednisone, 2.5 mg, twice daily. In
menwithprogressivemCRPC, early studies of abiraterone ac-
etate showedtumor responsewhencombinedwithdexameth-
asone, 0.5 mg, once daily,5,8 and subsequent reports de-
scribed tumor responses to abiraterone acetate after a switch
from prednisone to dexamethasone.9 Therefore, our fourth
treatment group receiveddexamethasone,0.5mg, oncedaily.
The primary end point was the absence of mineralocorticoid
excess in the first 24weeks of treatment. Additionally, we as-
sessed toxic effects related to glucocorticoid excess or andro-
gen suppression, effects on steroid biosynthesis, and antitu-
mor activity.
Methods
Patients and Study Design
In thisopen-label,parallel-arm,multicenter,phase2study, 164
asymptomaticorminimally symptomaticmenwithmCRPCre-
ceived abiraterone acetate 1000mg once daily andwere ran-
domly assigned in a 1:1:1:1 ratio, using an interactive web re-
sponse system and a computer-generated randomization
schedule, to 1 of 4 glucocorticoid regimens: prednisone, 5mg,
twice daily, prednisone, 5mg, oncedaily, prednisone, 2.5mg,
twice daily, or dexamethasone, 0.5 mg, once daily. The trial
protocol is available in Supplement 1. Study treatmentwas ad-
ministered in 28-day cycles without interruption. Partici-
pants were recruited at 22 centers in 5 countries (eTable 1 in
Supplement 2). They were required to have histologically or
cytologically confirmedprostate adenocarcinomawithmeta-
static disease documented by positive bone scan, computed
tomography scan, or magnetic resonance imaging and pros-
tate cancer progression documented by prostate-specific an-
tigen (PSA) according to the Prostate Cancer Working Group
210 or radiographically according to the modified Response
EvaluationCriteria InSolidTumors (RECIST)version 1.1.11Men
were surgically ormedically castrated, with testosterone lev-
els of less than 50 ng/dL. Men with visceral disease were ini-
tially excludeduntil a protocol amendment inNovember 2013
(after 61 patients had been accrued), when theywere permit-
ted to enroll. Patientswithprior cytotoxic chemotherapy, bio-
logic therapy, or inhibition of the androgen receptorwith abi-
raterone acetate plus prednisone for the treatment ofmCRPC
were excluded.
Theplannedmaximumdurationof themain studywas39
cycles (156 weeks) after the first participating patient started
study treatment. Patients continued the main study treat-
ment until disease progression, initiation of another prostate
cancer treatment, or discontinuation of study treatment for
either safety reasons (eg, sustained toxic effects that did not
return to grade ≤1 with appropriate medical management) or
patient request. At the end of themain study,men could con-
tinue treatment ina separate extensionprotocol. Patientswith
grade3or4hypokalemiaandthosewhorequireddiuretic treat-
ment, a change in glucocorticoid dose, or palliative radio-
therapydiscontinued themain study treatment but could en-
roll in the extension protocol and restart the main study
treatment after improvement to grade≤1without diseasepro-
gression. Themain studywas completed in August 2016, and
analyses were conducted from August 2017 to June 2018.
Study visits occurred on days 1 and 15 of cycle 1, day 1 of
cycles 2 to 6, day 1 of every 3 cycles thereafter, and 4 weeks
after completing the main study. Patients reported any ad-
verse events since the prior visit, and the investigator graded
each event using the National Cancer Institute Common Ter-
minologyCriteria forAdverseEvents (NCICTCAE)version4.0.
Patients with low potassium or prior history of hypokalemia
Key Points
Question What are the physiological effects associated with
abiraterone acetate plus various glucocorticoid regimens to treat
metastatic castration-resistant prostate cancer?
Findings In this open-label, phase 2 randomized clinical trial, the
164menwith metastatic castration-resistant prostate cancer
treated with abiraterone acetate plus prednisone, 5 mg, twice or
once daily, 2.5 mg twice daily, or dexamethasone, 0.5 mg, once
daily showed nomineralocorticoid excess toxic effects (grade1
hypokalemia or grade2 hypertension) through cycle 6. Insulin
resistance and loss of total body bonemineral density at the end
of study were only significant with dexamethasone.
Meaning Lowering glucocorticoid dose combined with
abiraterone acetate requires careful monitoring for toxic effects
related tomineralocorticoid excess.
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could undergo weekly or more frequent laboratory electro-
lyte evaluation. Additional procedures are described in the
eMethods in Supplement 2.
Thestudyprotocolandamendmentswereapprovedbythe
institutional review board at each participating site, and the
study was conducted according to the provisions of the Dec-
laration of Helsinki and the International Conference onHar-
monization of Good Clinical Practice Guidelines. All patients
provided written informed consent before participating.
Outcomes
The primary end point of nomineralocorticoid excess was de-
finedasexperiencingneitherof2mineralocorticoidexcess toxic
effects, grade≥1hypokalemiaor grade≥2hypertension,during
the first 24weeksof treatment (ie, 6 cycles). This endpointwas
derived from treatment emergent adverse event data, defined
using the Medical Dictionary for Regulatory Activities
(MedDRA)12 andgradedaccording toNCICTCAEv4.0. Second-
ary end points were global safety profile by NCI CTCAE v4.0;
changes inplasmaACTHandurinarymetabolites (eMethodsand
eTable 2 in Supplement 2); incidence of exogenous glucocorti-
coid adverse effects, namely changes in fasting serum insulin,
homeostatic model assessment of insulin resistance (HOMA-
IR;calculatedas insulin × glucose ÷ 22.5), total leanbodymass,
totalbodyfat, andbonemineraldensity;andclinicalbenefit, in-
cluding antitumor activity from serum PSA values, radio-
graphicprogression-freesurvival,andinfluenceonqualityof life
(based on the EuroQol 5-dimension questionnaire and Func-
tionalAssessmentofCancerTherapy-ProstateCancerquestion-
naire). Total lean body mass and total body fat were assessed
using bone density scan data.13 To avoid artifacts in interpreta-
tion due to bone metastases, we only report body fat changes
involvingthearmsandtotalbody.Anexploratorysecondaryob-
jective to evaluate associations with outcome and plasma an-
drogen receptor aberrations14 will be reported separately.
Trial Size Calculation and Statistical Analyses
The assumption was that for a glucocorticoid regimen to be
considered of interest, 75% of patients in a treatment group
would need to meet the primary end point, based on previ-
ously reported rates ina regulatoryphase3 trial.2 Ineach treat-
ment group, an exact binomial test with a 5% 1-sided signifi-
cance level had 89% power to detect the difference between
50%and75%with a sample size of at least 30patients; a treat-
ment groupwould be rejected if 50%of patients or fewermet
the primary end point. Analyses were conducted separately
within each group, and the study was neither designed nor
powered to compare results across groups.
Changes in steroid metabolites (after 2 cycles) and exog-
enousglucocorticoid adverse effects (at cycle 12 andat theend
of the main study) were examined with the Wilcoxon signed
rank test. Values for urinary metabolites after 2 cycles were
comparedamongpatientswhomet theprimaryendpoint and
those who did not at 24 weeks using the Wilcoxon 2-sample
test. Statistical significancewasdefinedasP < .05,withnocor-
rection for multiple testing. Missing values for the end-of-
main-study visit were imputed using the last-observation-
carried-forward method; for other time points, only patients
with data were included. Patient-reported quality of life was
summarized descriptively at baseline and at cycles 6 and 18.
Radiographicprogression-free survivalwas analyzedwith the
Kaplan-Meier product-limit method. The trial was not de-
signed to compare antitumor activity between the 4 treat-
ment groups.
Results
Patient Characteristics
Of 204 men assessed for study eligibility, 164 (median [range]
age, 70 [50-90] years) were randomly assigned between June
2013 andOctober 2014 to 1 of 4 glucocorticoid regimens (inten-
tion-to-treatpopulation) and163 receivedat least 1dose (safety
population) (Figure 1). Patient disposition details are provided
ineFigure 1 inSupplement2.Mostbaselinecharacteristicswere
balanced across treatment groups, although incidences of el-
evatedbloodpressure at baselinewere46.3% forprednisone, 5
mg, once daily and ranged from 26.8% to 33.4% in the other
groups. The mean time from diagnosis to randomization was
101.4months in the dexamethasone, 0.5mg, once daily group
and ranged from 59.6 to 69.2 months in the other groups
(eTable 3 in Supplement 2). Between 39.0% and 56.1% of pa-
tients (16to23patients) ineachtreatmentgroupweretakingany
antihypertensivemedicationatbaseline.Median treatmentex-
posurewas12.9monthsoverall (12.9, 10.6,8.4,and18.4months
intheprednisone,5mg, twicedaily,oncedaily,and2.5mgtwice
daily, and dexamethasone groups, respectively), with a maxi-
mum follow-up time on treatment of 35.6months.
Primary End Point
Of 163 patients who received any treatment, 19 discontinued
before week 24 without an adverse event of either grade 2 or
higher hypertension or grade 1 or higher hypokalemia; there-
fore, 144 patients were evaluable for the primary end point
(Figure 1). Of these patients, 85 (59.0%) experienced neither
grade 2 or higher hypertension nor grade 1 or higher hypoka-
lemia during the first 24 weeks of treatment andmet the pri-
mary end point. The breakdown by treatment group was 24
of 34 patients (71%; 95% CI, 54%-83%) treated with predni-
sone, 5 mg, twice daily, 14 of 38 patients (37%; 95% CI, 23%-
53%) treated with prednisone, 5 mg, once daily, 21 of 35 pa-
tients (60%; 95% CI, 44%-74%) treated with prednisone, 2.5
mg, twice daily, and 26 of 37 patients (70%; 95% CI, 54%-
83%) treatedwith dexamethasone (Table). The lower bound-
ary of the 95% CI was higher than 50% (the protocol-defined
criterion) with prednisone, 5 mg, twice daily and dexameth-
asonebut less than50%withprednisone, 5mg,oncedaily and
2.5mg twicedaily. Overall, grade 2or higher hypertensionoc-
curred in the first 24weeks in 49 (34.0%) of 144 evaluable pa-
tients, andgrade1orhigherhypokalemiaoccurred in18 (12.5%)
of 144 patients (Table), including 2 patients with grade 3 hy-
pokalemia in the prednisone, 5 mg, once daily group.
Treatment Effect on Steroid Biosynthesis
In keeping with the prednisone, 2.5mg, twice daily and 5mg
once daily groups not meeting the primary end point for ab-
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sence ofmineralocorticoid excess toxic effects, plasmaACTH
increasedsignificantlyduring treatment frombaseline tocycle
3 with abiraterone plus prednisone, 5 mg, once daily (me-
dian, 8.95 pmol/L; interquartile range [IQR], 4.39-12.63)
(P < .001) andabirateroneplusprednisone, 2.5mg, twicedaily
(median,3.97pmol/L; IQR,0.42-9.24) (P < .001).PlasmaACTH
didnot change significantlywithprednisone, 5mg, twicedaily
(median, −1.07 pmol/L; IQR, −3.08 to 0.30) (P = .16) and de-
creased significantly with dexamethasone (median, −1.82
pmol/L; IQR, −3.39 to −0.10) (P = .02) (Figure 2Aand eTable 4
in Supplement 2).
To further evaluate upregulation of steroids upstream of
CYP17A1 inhibition, urinary steroid metabolites were evalu-
ated. From baseline to cycle 3, deoxycorticosterone metabo-
lites significantly increased (all P < .001) with prednisone,
5 mg, twice daily (absolute median, 11.4 μg/24 h; IQR, −1.9 to
60.9 and median percentage change, 149%; IQR, −15% to
324%); 5 mg once daily (absolute median, 75.9 μg/24 h; IQR,
46.7 to 176.2andmedianpercentagechange,862%; IQR,351%-
1491%); and2.5mg twice daily (absolutemedian, 100.5 μg/24
h; IQR,36.9 to 158.6andmedianpercentagechange,716%; IQR,
402%-1391%) but not with dexamethasone (Figure 2B and
eTable4 in Supplement 2). Corticosteronemetabolites signifi-
cantly increased (each P < .001) with prednisone, 5 mg, once
daily (absolute median, 4452.6 μg/24 h; IQR, 2610.2-6573.0
andmedian percentage change, 984% IQR, 622%-1851%) and
prednisone,2.5mg, twicedaily (absolutemedian,4913.5μg/24
h; IQR, 1650.6 to7787.9andmedianpercentagechange, 1016%;
IQR, 471%-1846%) (eFigure 2A and eTable 4 in Supple-
ment 2). At first assessment, at cycle 3, median suppression
Figure 1. Trial Consort Diagram
204 Patients assessed for eligibility
41 Assigned to treatment
(intention-to-treat
analyses)
41 Assigned to treatment
(intention-to-treat
analyses)
40 Assigned to treatment
(intention-to-treat
analyses)
42 Assigned to treatment
(intention-to-treat
analyses)
Prednisone, 5 mg,
twice daily
Prednisone, 5 mg,
once daily
Prednisone, 2.5 mg,
twice daily
Dexamethasone, 0.5 mg,
once daily
40 Excluded
39 Did not meet inclusion criteria
1 Declined to participate
41 Received assigned
treatment
(safety analyses)
41 Received assigned
treatment
(safety analyses)
39 Received assigned
treatment
(safety analyses)
42 Received assigned
treatment
(safety analyses)
34 Evaluable for primary
end pointa
38 Evaluable for primary
end pointa
35 Evaluable for primary
end pointa
37 Evaluable for primary
end pointa
7 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
3 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
4 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
5 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
164 Randomly assigned
a Evaluable patients completed the
24 weeks of treatment or
discontinued treatment early and
experienced either hypertension
(National Cancer Institute Common
Terminology Criteria for Adverse
Events grade2) or hypokalemia.
Reasons for treatment
discontinuation are provided in the
eFigure in the Supplement.
Table. Primary End Point: Mineralocorticoid Excess Adverse Events During the First 24Weeks
Variable
Treatment Groupa
Prednisone,
5 mg, Twice
Daily (n = 34)b
Prednisone,
5 mg, Once Daily
(n = 38)b
Prednisone,
2.5mg, Twice Daily
(n = 35)b
Dexamethasone,
0.5mg, Once Daily
(n = 37)b
Met the primary end pointc
No. (%) 24 (71) 14 (37) 21 (60) 26 (70)
95% CI (54-83) (23-53) (44-74) (54-83)
Investigator reported an adverse event
Grade ≥2 hypertension and grade
≥1 hypokalemia, No. (%)
2 (6) 1 (3) 3 (9) 2 (5)
Grade ≥2 hypertension alone,
No. (%)
7 (21) 18 (47) 10 (29) 6 (16)
Grade ≥1 hypokalemia alone,
No. (%)
1 (3) 5 (13) 1 (3) 3 (8)
a Patients in all treatment groups
received abiraterone acetate.
b Patients completed the 24 weeks of
treatment (6 cycles) or
discontinued treatment early and
experienced either hypertension
(National Cancer Institute Common
Terminology Criteria for Adverse
Events grade2) or hypokalemia.
c Investigator reported neither
hypertension (National Cancer
Institute Common Terminology
Criteria for Adverse Events grade
2) nor hypokalemia during the
first 24 weeks (6 cycles).
Research Original Investigation Safety of GlucocorticoidWith Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
E4 JAMAOncology Published online June 27, 2019 (Reprinted) jamaoncology.com
Downloaded From: https://jamanetwork.com/ by a University College London User  on 07/22/2019
of urinary excretionofmajor androgenmetabolites androste-
rone (eFigure 2B in Supplement 2) and dehydroepiandros-
terone (eFigure 2C in Supplement 2) was greater than 90%
(eTable 4 in Supplement 2). Androgen precursor metabolites
were also significantly suppressed (both P < .001) with pred-
nisone, 5 mg, twice daily (absolute median, −330.8 μg/24 h;
IQR, −555.5 to −165.8 and median percentage change, −81%;
IQR, −89% to −63%) and dexamethasone (absolute median,
−262.1 μg/24 h; IQR, −369.0 to −89.5 andmedian percentage
change, −88%; IQR, −93% to −56%). However, androgen pre-
cursormetaboliteswerenotsignificantlysuppressedwithpred-
nisone, 5 mg, once daily or 2.5 mg twice daily (Figure 2C and
eTable 4 in Supplement 2).
In exploratory analyses, 24-hoururinary excretionof cor-
ticosterone metabolites (eFigure 3A in Supplement 2), corti-
sol (Figure 2D), and cortisone (eFigure 3B in Supplement 2)
were significantly higher in patients in any treatment group
who experienced grade 2 or higher hypertension or grade 1 or
higher hypokalemia in the first 24 weeks of the study com-
paredwith patients without either adverse event (eTable 5 in
Supplement 2).
Adverse Events
Over the main study, grade 3 adverse events of hypertension
were reported in 7% (n = 3), 22% (n = 9), 13% (n = 5), and 7%
(n = 3) of patients in the prednisone, 5 mg, twice daily, pred-
nisone, 5mg, once daily, prednisone, 2.5mg, twice daily, and
dexamethasonegroups, respectively.Grade3hypokalemiawas
reported in 7.3% (n = 3) of patients in the prednisone, 5 mg,
once daily group and in no other patients; all other events of
hypokalemia were grade 1 or grade 2 (eTable 6 in Supple-
ment 2). Neither grade 4 hypokalemia nor grade 4 hyperten-
Figure 2. Changes FromBaseline to Cycle 3 in the 4 Treatment Arms and the AssociationWith Toxic Effects
of Sum ofMetabolites of Cortisol at Cycle 3
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sion were reported, and no patient discontinued study treat-
ment for persistent hypertension. One patient in the
prednisone, 5mg, once daily groupwith an unrelated gastro-
intestinal illness had a prolongedhospitalization for a serious
adverse event of hypokalemia. No patient had a serious ad-
verse event of hypertension. Cumulative incidences of hyper-
tension and hypokalemia over time are shown in eFigure 4 in
Supplement 2. Other adverse events of interest such as pe-
ripheral edema, cardiac effects, and liver function are sum-
marized in eTable 7 in Supplement 2.
Long-TermMetabolic andMusculoskeletal Effects
Insulin resistancewas evaluatedby recording changes in fast-
ing serum insulin or HOMA-IR. The mean change from base-
line for fastingseruminsulin inallpatientswas9.2pmol/L (95%
CI, −14.5 to 33.0) at cycle 12 and 17.7 pmol/L (95%CI, 1.0-34.3)
at the end of the main study. Significant increases in fasting
serum insulin andHOMA-IRwere observed in the dexameth-
asone group only, both at cycle 12 (fasting serum insulin, 53.7
pmol/L; 95% CI, 16.6-90.8; P < .001 and HOMA-IR, 2.15; 95%
CI,0.24-4.07;P = .004) (Figure3A,B)andat theendof themain
study (fasting serum insulin, 47.5 pmol/L; 95% CI, 18.8-76.2;
P = .002andHOMA-IR, 1.99; 95%CI, 0.59-3.38;P = .01) (eFig-
ure 5 in Supplement 2). No patient required insulin. Two pa-
tients started medications for non–insulin-dependent diabe-
tes (both were in the dexamethasone group).
Body composition showed a significant decrease in total
lean bodymass from baseline to cycle 12 in the prednisone, 5
mg, twice daily (−5.8%; 95% CI, −8.6% to −3.0%) (P < .001),
prednisone, 5mg, oncedaily (−2.5%; 95%CI, −4.9% to -0.0%)
(P = .02), and prednisone, 2.5mg, twice daily groups (−5.6%;
95%CI, −8.5% to−2.6%;P < .001) (Figure 3C) and in all groups
at the end of the main study (eFigure 5 in Supplement 2). In
keepingwithhigher glucocorticoid exposure, a significant in-
crease in total body fat in theprednisone, 5mg, twicedaily and
dexamethasone groups was observedwhen comparing base-
Figure 3. Changes FromBaseline to Cycle 12 by Treatment Group
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line to cycle 12 (12.3%; P = .001 and 19.2%; P < .001, respec-
tively) (Figure 3D) or to the end of the main study (eFigure 5
in Supplement 2) but was not observedwith the lower gluco-
corticoid regimens. A small but significant decrease in total
bodybonemineraldensity frombaseline to theendof themain
studywas seen in the dexamethasone group (−2.0%; 95%CI,
−3.4% to −0.6%); no other change in the bone mineral den-
sity of the total body or the arms was observed at cycle 12 or
at the end of the main study (eTable 8 in Supplement 2).
Clinical Benefit
Among the 164 randomized patients evaluated, a PSA de-
crease of greater than or equal to 50%was observed in 26 pa-
tients (63.4%; 95% CI, 48.1%-76.4%) treated with predni-
sone, 5 mg, twice daily, 32 (78.0%; 95% CI, 63.3%-88.0%)
treatedwithprednisone, 5mg, oncedaily, 24 (60.0%; 95%CI,
44.6%-73.7%) treatedwithprednisone,2.5mg, twicedaily, and
37 (88.1%; 95% CI, 75.0%-94.8%) treated with dexametha-
sone (Figure 4 and eTable 9 in Supplement 2). Median radio-
graphic progression-free survival was 18.5 months (95% CI,
10.0-26.7)withprednisone,5mg, twicedaily, 15.3months (95%
CI, 8.4-29.5) with prednisone, 5 mg, once daily, 12.8 months
(95% CI, 7.4-20.9) with prednisone, 2.5 mg, twice daily, and
26.6 months (95% CI, 20.9-not evaluable) with dexametha-
sone (eFigure 6A in Supplement 2). Patient-reported quality
of life in this population, which was asymptomatic or mini-
mallysymptomaticpretreatment, remainedstable inallgroups,
supporting no detectable reduction secondary to treatment
(eFigure 6B in Supplement 2).
Discussion
Abirateroneacetateplusprednisone isbeingusedearlier in the
treatment paradigm for prostate cancer and because patients
benefit for a longer period, treatment exposure is increased.
Figure 4. Prostate-Specific Antigen Declines by Treatment Group
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We therefore designed a randomized clinical trial to support
physician decision making in selecting a glucocorticoid regi-
men that balances controllingmanifestations of endogenous
mineralocorticoid excess with the adverse consequences of
nonphysiological exposure to exogenous glucocorticoids.
Manifestations of endogenous mineralocorticoid excess of-
ten present within 24 weeks of treatment, whereas the ad-
verse consequences associated with exogenous glucocorti-
coids are usually associated with cumulative exposure.
Prednisone, 5 mg, twice daily and dexamethasone, 0.5 mg,
oncedailymet theprespecified threshold for theprimary end
point (the95%CIexcluded50%mineralocorticoidexcess), but
prednisone, 5 mg, once daily and 2.5 mg twice daily did not
meet the threshold.
We selected hypertension and hypokalemia as indicators
of clinically relevant mineralocorticoid excess because other
clinical features, including lower limbedemaandgeneral fluid
overload, are less feasible to standardize in amulticenter trial.
To support our clinical end point, we confirmed a significant
rise in plasma ACTH and a subsequent rise in mineralocorti-
coidproductionwith the lowerprednisonedoses.Wehypoth-
esize thatmonitoringofurinaryglucocorticoidmetabolite lev-
els could identify patients at risk of mineralocorticoid excess
and allow tailoring of the glucocorticoid dose.
A strength of the trial was monitoring for long-term ad-
verseeffectsof glucocorticoidexcess.Total leanbodymassde-
creased significantly in all 3 prednisonegroups and total body
fat increased significantly in theprednisone, 5mg, twicedaily
anddexamethasonegroups. Significant increases in insulin re-
sistance and decreases in total bonemineral densitywere ob-
served onlywith dexamethasone. Androgen precursorswere
significantly suppressed with dexamethasone, 0.5 mg, once
daily and prednisone, 5mg, twice daily. The antitumor activ-
ity associatedwith abiraterone acetate plus glucocorticoids in
thepresent studywas similar to previous reports1,2 in this dis-
ease setting; dexamethasone appearedparticularly active but
may be associated with adverse metabolic consequences.
Limitations
A limitation of the trial is that the size calculation was based
ontheprimaryendpoint related to thesafetyof individual regi-
mens; therefore, the number of patients accrued does not al-
lowfordirect comparisonsamong the4 treatmentgroups. Sec-
ond, althoughpatientswere randomly assigned to treatment,
differences at baseline could contribute to differences in out-
comes. Third, testing for physiological effects and their asso-
ciation with clinical manifestation of mineralocorticoid ex-
cess were exploratory analyses, and we did not correct for
multiple testing. Overall, the observations of our phase 2 trial
require further validation.
Conclusions
This trial provides results consistentwith the approveduse of
abiraterone acetatewith prednisone, 5mg, twice daily for the
treatment ofmCRPC. Long-termadversemetabolic andmus-
culoskeletal changes are small anddonot appear tohaveadet-
rimental effectonpatient-reportedqualityof life.Differentglu-
cocorticoid regimens make distinct compromises on control
ofmineralocorticoidexcess, changes inbodycomposition, and
development of insulin resistance. With careful monitoring,
the risk of hypokalemia with lower glucocorticoid doses can
be mitigated, as demonstrated in the LATITUDE and STAM-
PEDE trials where no major safety concerns were raised.3,4 A
lowerdose of prednisone appears to reduce long-term risks of
insulin resistance, increased body fat, and loss of bone min-
eral density.
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